Medical News

[ Subclinical Hypothyroidism Treatment Reduces Ischemic Heart Disease Event Risk In Younger Patients ]

Subclinical Hypothyroidism Treatment Reduces Ischemic Heart Disease Event Risk In Younger Patients

A study published in Archives of Internal Medicine reveals that younger patients with subclinical hypothyroidism (SCH) who receive the medication levothyroxine are less likely to experience ischemic heart disease events. However, according to the researchers, this finding was not seen in older patients. SCH is a relatively common condition in which the thyroid gland does not produce enough thyroid hormone. Although the condition is often asymptomatic, recent studies have indicated that SCH is linked with increased cardiovascular events and mortality, especially in young and middle-aged patients. However, the researchers highlight that those epidemiologic associations do not verify that treatment of SCH would be effective. The researchers explain: "Thus, only adequately powered randomized controlled intervention trials will be able to demonstrate whether treatment of SCH is worthwhile in terms of improvement in both cardiovascular disease risk and symptoms.

Subclinical Hyperthyroidism Linked To Higher Atrial Fibrillation And Coronary Heart Disease Risk

A study published in Archives of Internal Medicine reveals that subclinical hyperthyroidism (SCH) may be linked to a greater risk of total mortality, coronary heart disease (CHD) death, as well as incident atrial fibrillation (AF). The findings also indicate that the risk of AF and CHD death is higher when thyrotropin levels are below 0.10 mIU/L. SCH is a relatively common condition defined by low thyrotropin levels with normal concentrations of free thyroxine (FT 4 ) and triiodothyronine (T 3 ). Earlier studies have suggested that SCH, which is often asymptomatic, is linked to cardiovascular system effects, increased heart rate, incident AF, as well as CHD. However, these prospective studies have produced conflicting results and conclusions from study-level meta-analyses have been contradicting.

Girls Who Start Puberty Very Early At Increased Risk Of Psychological Problems

Girls who start puberty very early are more likely to have psychological problems and be at risk of sexual abuse and early pregnancy, suggests a new review published in The Obstetrician & Gynaecologist (TOG). Puberty is characterised by the maturation of the hypothalamic pituitary gonadal (HPG) axis, which plays a critical part in the development and regulation of the reproductive system. Normal puberty commences from approximately 10 years onwards and breast development is usually the first sign of this. In Europe, the lower end of the normal range for the onset of puberty is 8 years in girls, although there are ethnic variations. In girls, early puberty or precocious puberty is defined as the development of secondary sexual characteristics, such as the development of breasts or pubic hair before the age of 8 years.

Understanding Of Breast Cancer's Multiple Varieties Improved By New Data

New findings presented at Europe's leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers. Focused on the biological features that make tumors more or less sensitive to important therapies, the new studies will help doctors make crucial choices about the most appropriate treatment for millions of patients. "Despite major advances in the treatment of breast cancer many patients continue to relapse and die from the disease, " noted Prof Mitch Dowsett from the Royal Marsden Hospital, UK, former IMPAKT Chair. "Studies presented at this year's IMPAKT further emphasize the potential of biomarkers to identify new targets for developing therapy to disease that is resistant to our current treatments as well as the groups of patients most likely to respond to the new treatments.

Protection Provided By Estrogen Hormone After Traumatic Brain Injury

With more than 1.7 million people sustaining a traumatic brain injury each year, the need to identify processes to limit inflammation and subsequent damage is critical. Approximately 275, 000 people are hospitalized annually with traumatic brain injury, leaving 85, 000 with long-term disabilities and taking the lives of more than 50, 000. More than 5 million people live with disabilities caused by traumatic brain injuries, often the result of car accidents and falls. Direct and indirect costs exceed $75 billion. Dr. Joshua Gatson, Assistant Professor of Surgery at the University of Texas Southwestern Medical Center in Dallas, investigates biomarkers and novel therapies for traumatic brain injury. His previous work has shown that estrone, one of the three naturally occurring estrogen hormones in the body, has shown some promise in reducing inflammation and cell death in the brain.


Medical News © Nanda
Designer Damodar